Pharmesis to acquire remaining 19% stake in Sichuan Longlife Pharmaceutical
This agreement was finalised on 23 September.
Pharmesis International Ltd. has announced that its wholly-owned subsidiary, Chengdu Kinna Pharmaceutical Co., Ltd., has signed a conditional sale and purchase agreement to acquire the remaining 19% equity interest in Sichuan Longlife Pharmaceutical Co., Ltd.
This agreement was finalised on 23 September.
The equity interest will be acquired from Chengdu Kinna Investment Co., Ltd., under the terms and conditions outlined in the SPA.
The acquisition is part of Pharmesis International's strategic efforts to enhance its portfolio and strengthen its position in the pharmaceutical industry.